Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-21-008019
Filing Date
2021-06-04
Accepted
2021-06-04 16:30:47
Documents
5
Period of Report
2021-07-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20210707xdef14a.htm DEF 14A 433872
2 GRAPHIC tmb-20210707xdef14a015.jpg GRAPHIC 112513
3 GRAPHIC tmb-20210707xdef14a014.jpg GRAPHIC 104976
4 GRAPHIC tmb-20210707xdef14a004.jpg GRAPHIC 2463
5 GRAPHIC tmb-20210707xdef14a003.jpg GRAPHIC 5525
  Complete submission text file 0001558370-21-008019.txt   746225
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 21996887
SIC: 2836 Biological Products, (No Diagnostic Substances)